Associated Genetic Biomarkers
NCI Definition: A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma. 
Angiosarcomas most frequently harbor alterations in MYC, TP53, KDR, FLT4, and CRKL .
MYC Amplification, TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and KDR Mutation are the most common alterations in angiosarcoma .
There are 17 clinical trials for angiosarcoma, of which 16 are open and 1 is completed or closed. Of the trials that contain angiosarcoma as an inclusion criterion, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 12 are phase 2 (12 open), and 1 is phase 3 (0 open).
PIK3CA, PTEN, and RB1 are the most frequent gene inclusion criteria for angiosarcoma clinical trials .
Nivolumab, paclitaxel, and pazopanib are the most common interventions in angiosarcoma clinical trials.
Significant Genes in Angiosarcoma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.